Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730483 · ClinicalTrials.gov registry record · NA
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT00730483 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 13 participants.
The verdict
NCT00730483, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.
Interventions
- DRUG PVA microporous hydrospheres/doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730483
The ClinicalTrials.gov registry entry for NCT00730483 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PVA microporous hydrospheres/doxorubicin hydrochloride is the first listed.
NCT00730483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730483 about?
NCT00730483 is a clinical study titled "Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors". RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor an...
What is the current status of trial NCT00730483?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2009-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00730483?
The interventions under investigation include: PVA microporous hydrospheres/doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00730483?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.